Abbott Invests in U.S. Manufacturing for Health Tech Expansion

Abbott Laboratories is expanding its U.S. manufacturing and R&D footprint with significant new investments across three states, aiming to boost the production of cardiovascular devices and diagnostics. The company will build a new cardiovascular device manufacturing facility in Georgia, projected to be operational by 2028. This expansion follows strong U.S. performance in the company's cardiovascular business.

Further strengthening its diagnostics division, Abbott is investing $500 million to expand manufacturing for transfusion diagnostics. This investment is expected to create over 300 new American jobs. These moves underscore Abbott's commitment to domestic production and the U.S. market.

The diagnostics expansion allows Abbott to enter the molecular nucleic acid blood and plasma testing market, estimated at $1 billion. The company will introduce its Alinity n system, designed for molecular testing of DNA and RNA for multiple pathogens, complementing its existing Alinity s system for serology screening. This enhancement aims to improve the safety of blood transfusions by detecting infectious diseases like HIV and hepatitis.

Abbott has invested over $15 billion in its U.S. operations over the past five years, encompassing manufacturing, equipment, and R&D. With 35 manufacturing sites and 43 R&D centers across the country, the company maintains a substantial presence in the United States. These latest investments reinforce Abbott's position in the health technology sector and support its global supply chain resilience.